re: http://bbs.wenxuecity.com/health/534638.html
I hope this helps:
Gutierrez醫師是南美移民，英文應該不是第一語言吧， 難免影響與人溝通。 他也做很多研究。當然會壓縮他和病人溝通的時間。 美國醫師裏近4分之一？是內科醫師，match時招不足美國醫學院畢業生，招外國醫學院畢業生很正常。大醫院醫師做研究也非常常見， 很正常。 不喜歡他的話，該癌症中心醫師很多，換人吧。打個電話問問還有誰是GI癌症專業的。換人就行。因為是在同一個醫院，治療也不會因此拖延很久。疑人不用很重要。
http://jtcancercenter.org/physicians_2/martin-gutierrez-m-d/
Home > Physicians > Martin Gutierrez, M.D.
Martin Gutierrez, M.D.
Martin E. Gutierrez, M.D. is Director of the Drug Discovery and Phase I Unit at the John Theurer Cancer Center at Hackensack University Medical Center. Under Dr. Guiterrez’s leadership, John Theurer Cancer Center works closely with industry, the National Cancer Institute-National Institutes of Health (NCI-NIH) and other academic institutions to expand its Phase I portfolio. Dr. Gutierrez also serves as Medical Oncologist in the division of Thoracic Oncology and Gastrointestinal Oncology.
Dr. Gutierrez brings extensive expertise leading Phase I and early stage cancer treatment research to the John Theurer Cancer Center. He has nearly two decades of drug discovery experience, including many years with the NCI-NIH and other leading institutes helping to bring new treatments to patients.
Prior to joining the John Theurer Cancer Center, Dr. Gutierrez supported numerous research initiatives at the NCI-NIH, serving as Head of the Office of NCI-Navy Oncology and the Lung Cancer Clinical Research Section. Most recently, Dr. Gutierrez served as the Medical Director of Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital in Fort Lauderdale where he launched the only Phase I Unit in South Florida.
His research interest includes the development of novel therapeutics for solid tumors. He is widely published in peer-reviewed journals, including Journal of Clinical Oncology and Clinical Cancer Research.
Dr. Gutierrez completed his medical oncology fellowship at the NCI and his hematology fellowship at the NIH’s National Heart Lung and Blood Institute. He earned his residency at Boston Medical Center and his medical degree at Javeriana University School of Medicine in Bogota, Colombia.
- Medical Education: Javeriana University School of Medicine
- Residency and Chief Resident: Internal medicine, Boston Medical Center, Boston University
- Fellowship: Medical oncology, National Cancer Institute, and hematology, National Heart Lung and Blood Institute, National Institutes of Health
- Board Certifications: Hematology, medical oncology, internal medicine
- Specializations: Drug discovery and Phase I clinical research
- Research Interests: Supported numerous research initiatives at the NCI-NIH
- Targeted therapies
- Personalize medicine
- Honors/Awards: Reviewer for scientific journals, including Clinical Cancer Research, The Cancer Journal, and Cancer Chemotherapy and Pharmacology
- Memberships: American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Massachusetts Medical Society
Dr. Gutierrez clinical trials
- A multi-center, open-label phase IB study of escalating doses of RO5045337, in oral small molecule MDM2 antagonist, in combination with Doxorubicin in patients with Soft Tissue Sarcoma. NP28021
- A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer IMGN 007
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed BMS-CA 209039
- A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS) D3610C00003 (GU 86)
- Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer CBEZ235D2101
- Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONX 0912 in Patients with Hematological Malignancies 2011-001
- A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies KCP-330-001
